Bleomycin Chemotherapy

Bleomycin Chemotherapy

1st Edition - January 28, 1985

Write a review

  • Editors: Branimir Ivan Sikic, Marcel Rozencweig, Stephen K. Carter
  • eBook ISBN: 9781483265025

Purchase options

Purchase options
DRM-free (PDF)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Bleomycin Chemotherapy focuses on the clinical uses of bleomycin. Bleomycin, a group of glycopeptides isolated from Streptomyces verticillus, has a unique structure and mechanism of action among anticancer drugs. The drug’s remarkable lack of bone marrow toxicity prompted its addition to myelosuppressive regimens and enabled treatment of patients with compromised hematopoietic function. Bleomycin is an integral component of one of the great triumphs of medical oncology—the curative treatment of metastatic testicular carcinomas. Similar curative potential has been demonstrated for bleomycin in combination with cisplatin and vinblastine in germ-cell cancers of the ovary. Bleomycin is included in several important treatment regimens for Hodgkin's disease and non-Hodgkin's lymphomas. The drug also has clinical activity against squamous carcinomas of various sites. These uses and other aspects, including the development of new bleomycin analogs, are discussed in the following chapters, which were first presented at a symposium jointly sponsored by the Northern California Cancer Program and Bristol Laboratories in San Francisco, California, 14-15 September 1984.

Table of Contents


  • Contributors

    Preface

    I. Introduction

    1. Bleomycin: More than a Decade Later

    I. Introduction

    II. Testicular Cancer

    III. Hodgkin's Disease

    IV. Non-Hodgkin's Lymphoma

    V. Head and Neck Cancers

    VI. Uterine Cervical Cancer

    VII. Conclusion

    References

    2 Clinical Pharmacology of Bleomycin

    I. Pharmaceutical Properties

    II. Mechanism of Action

    III. Pharmacokinetics

    IV. Clinical Use

    References

    II. Testicular and Ovarian Cancers

    3. Chemotherapy of Testicular Carcinoma: An Overview

    I. Introduction

    II. Chemotherapy

    III. Prognostic Variables

    IV. Toxicity

    V. Conclusion

    References

    4. The Memorial Hospital Experience in the Management of Testicular Germ-Cell Tumors

    I. Introduction

    II. The VAB II Regimen

    III. The VAB III Regimen

    IV. VAB IV and VAB V Regimens

    V. The VAB VI Regimen

    VI. Adjuvant Surgery

    VII. Conclusion

    References

    5. Effective Treatment of Malignant Ovarian Germ-Cell Tumors with Cisplatin, Vinblastine, and Bleomycin (PVB)

    I. Introduction

    II. Methods

    III. Results

    IV. Discussion

    References

    III. Head and Neck Cancer

    6. The Role of Chemotherapy in the Treatment of Head and Neck Cancer

    I. Introduction

    II. Salvage Treatment

    III. Primary Treatment

    IV. Prognostic Factors

    V. Conclusions

    References

    7. Head and Neck Cancer: Bleomycin plus Radiotherapy

    I. Introduction

    II. Randomized Studies

    III. Nonrandomized Studies

    IV. Normal Tissue Effects of Combined Treatment

    V. Discussion

    References

    8. The Role of Induction Chemotherapy in Combined-Modality Treatment Programs

    I. Introduction

    II. Effect on Treatment and Survival

    III. Testicular Cancer

    IV. Osteosarcoma

    V. Head and Neck Cancer

    VI. Discussion

    VII. Summary

    References

    9. Induction Chemotherapy in the Treatment of Head and Neck Cancer: SUNY Buffalo and VAMC Experience

    I. Introduction

    II. Methods

    III. Results

    IV. Discussion

    V. Conclusion

    References

    IV. The Malignant Lymphomas

    10. Hodgkin's Disease: an Overview and ABVD Studies in Milan

    I. Introduction

    II. MOPP versus ABVD

    III. Salvage Treatment

    IV. Cyclic MOPP/ABVD

    V. Conclusion

    References

    11. Bleomycin in Combination with MOPP in the Management of Advanced Hodgkin's Disease: A Southwest Oncology Group Experience

    I. Introduction

    II. Patients and Methods

    III. Results

    IV. Discussion

    References

    12. Combined-Modality Studies in the Treatment of Hodgkin's Disease

    I. Background

    II. Prospective Clinical Trials

    III. Combined-Modality Therapy in Pediatric Hodgkin's Disease

    IV. Future Directions

    References

    13. The Non-Hodgkin's Lymphomas: an Overview

    I. Low-Grade Lymphomas

    II. Intermediate-Grade Lymphomas

    III. High-Grade Lymphomas

    IV. Future Directions

    References

    14. Non-Hodgkin's Lymphomas: Milan Studies

    I. Introduction

    II. Combined-Modality Therapy for Stage I to Stage II Disease

    III. Alternating Chemotherapy in Stage III to Stage IV Disease

    IV. Conclusion

    Reference

    15. BACOP and Related Studies in Non-Hodgkin's Lymphoma

    I. Single-Agent Bleomycin

    II. Bleomycin in Chemotherapy Combinations

    III. Four- and Five-Drug Regimens

    IV. Therapeutic Programs Using Continuous-Infusion Bleomycin

    V. New Intensive-Treatment Multidrug Regimens

    References

    V. Non-Small-Cell Lung Cancer

    16. A Reassessment of Bleomycin in Lung Cancer and Other Intrathoracic Neoplasms

    I. Systemic Therapy of Lung Cancer

    II. Locally Directed Therapy

    III. Role in Treating Mesothelioma

    IV. Future Directions

    References

    17. Non-Small-Cell Lung Cancer: Bleomycin plus Etoposide and Cisplatin

    I. Introduction

    II. Patients and Methods

    III. Results

    IV. Discussion

    References

    VI. Cervical Cancer

    18. Cervical Cancer: Bleomycin Studies—An Overview

    I. Introduction

    II. Single-Agent Chemotherapy

    III. Combination Chemotherapy Including Bleomycin

    References

    19. Bleomycin in Cervical Carcinoma: Protocols of the Northern California Oncology Group

    I. Introduction

    II. NCOG Protocol 5C81

    III. NCOG Protocol 5C91

    IV. Discussion

    References

    VII. Pulmonary Toxicity

    20. Pulmonary Toxicity of Bleomycin

    I. Incidence and Risk Factors

    II. Clinical Features

    III. Pathogenesis and Histopathology

    IV. Clinical Management

    V. Future Directions

    References

    VIII. Other Uses

    21. Bleomycin: The Search for Other Indications

    I. Single-Agent Activity of Bleomycin

    II. Squamous-Cell Carcinomas

    III. Primary Brain Tumors

    IV. Superficial Bladder Tumors

    V. Kaposi's Sarcoma

    VI. Intracavitary Therapy

    VII. Recommendations for Future Studies

    VIII. Bleomycin in Combination Therapy

    References

    IX. New Bleomycins

    22. Peplomycin and Tallysomycin S10b: Two Bleomycin Analogs

    I. Introduction

    II. Chemistry

    III. Antitumor Screening Activity

    IV. Mechanisms of Action

    V. Preclinical Toxicology

    VI. Pharmacology

    VII. Clinical Studies

    VIII. Conclusion

    References

    23. New Analogs and Derivatives of Bleomycin

    I. Total Synthesis of Bleomycin and Preparation of Bleomycin Analogs

    II. Preparation of New Bleomycins and Their Derivatives

    III. Screening of Derivatives for Clinical Study

    IV. Liblomycin

    References

    X. Summary and Prospects

    24. Bleomycin: Future Prospects

    I. Introduction

    II. Combination Chemotherapy

    III. Bleomycin and Radiotherapy

    IV. Future Directions

    V. Summary

    References

    25. Bleomycin in Chemotherapy: Summary and Closing Remarks

    I. Chemistry

    II. Pharmacokinetics

    III. Toxicity

    IV. Antitumor Activity

    V. Future Considerations

    VI. Summary

    References


Product details

  • No. of pages: 335
  • Language: English
  • Copyright: © Academic Press 1985
  • Published: January 28, 1985
  • Imprint: Academic Press
  • eBook ISBN: 9781483265025

About the Editors

Branimir Ivan Sikic

Marcel Rozencweig

Stephen K. Carter

Ratings and Reviews

Write a review

There are currently no reviews for "Bleomycin Chemotherapy"